Bone Metastasis on the Survival of Gefitinib Effective Patients
Status:
Completed
Trial end date:
2015-07-12
Target enrollment:
Participant gender:
Summary
Gefitinib is a selective small molecule epidermal growth factor receptors (EGFR) tyrosine
kinase inhibitors (EGFR-TKI), it's curative effect on non-small cell lung cancer (NSCLC) has
been confirmed by a number of prospective clinical trials. The researches aim to analysis
whether bone metastasis could affect the survival of NSCLC patients who were effective in
Gefitinib treatment over 6 months.